Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series

Publisher： Karger

E-ISSN： 1421-9832|228|3|211-214

ISSN： 1018-8665

Source： Dermatology, Vol.228, Iss.3, 2014-03, pp. : 211-214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab for the Treatment of Refractory Adamantiades-Behçet Disease with Articular, Intestinal, Cerebral and Ocular Involvement

By  

Dermatology, Vol. 220, Iss. 3, 2010-01 ,pp. : 282-286

Karger

Access to resources Recommend Favorite

Successful Treatment of Refractory Skin Manifestations of Systemic Lupus Erythematosus with Rituximab: Report of a Case

By  

Dermatology, Vol. 216, Iss. 3, 2008-01 ,pp. : 257-259

Karger

Access to resources Recommend Favorite

Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet’s Syndrome

By  

Dermatology, Vol. 222, Iss. 2, 2011-04 ,pp. : 123-127

Karger

Access to resources Recommend Favorite

Mycophenolate Mofetil Is Ineffective in the Treatment of Mucocutaneous Adamantiades-Behçet’s Disease

By  

Dermatology, Vol. 203, Iss. 4, 2001-12 ,pp. : 322-324

Karger

Access to resources Recommend Favorite

Long-Term Effects of Interferon Alpha 2A Treatment in Behçet’s Disease

By  

Dermatology, Vol. 201, Iss. 1, 2000-08 ,pp. : 40-43

Karger

Access to resources Recommend Favorite